GlassScriptPhysician profile
C Andrew Schroeder
NPI 1386755346
$268,237.51
in general payments reported to CMS, 2019-2025
43 companies · $1,203 in 2025
The $1,203 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $15K · 2021: $48K · 2022: $100K · 2023: $74K · 2024: $19K · 2025: $1,203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $82K · Travel and Lodging: $5,244 · Food and Beverage: $4,024 · Consulting Fee: $2,925.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $81,900.00 |
| Travel and Lodging | $5,244.30 |
| Food and Beverage | $4,023.92 |
| Consulting Fee | $2,925.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $261,968.16 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Viiv Healthcare Company | $1,600.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $1,039.60 | 2019-2024 | Fasenra, Tezspire |
| Abbvie INC. | $544.71 | 2019-2025 | Ubrelvy |
| Janssen Biotech, INC. | $327.76 | 2024-2025 | Tremfya, Stelara |
| Lilly USA, LLC | $227.19 | 2019-2025 | Mounjaro, Zepbound, Omvoh |
| Aimmune Therapeutics, INC. | $204.69 | 2024-2025 | Vowst |
| Mallinckrodt Hospital Products INC. | $194.77 | 2020-2023 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.43 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $144.00 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $128.29 | 2019-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $121.07 | 2019-2020 | |
| Mylan Specialty L.P. | $101.08 | 2019-2024 | Yupelri |
| Qol Medical, LLC | $94.40 | 2024-2025 | Sucraid, Sucraid |
| Circassia INC. | $92.79 | 2019-2020 |
Show all 42 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw C Schroeder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.